Conditions: Migraine
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 3
Healthy volunteers: no

Brief summary:
Olanzapine (o-lan-zah-peen) is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with schizophrenia and/ or bipolar disorder. The trade name for this drug is Zyprexa®. Olanzapine has not been approved by the FDA for the prevention of migraine and is experimental for the purposes of this research study.

The Jefferson Headache Center at Thomas Jefferson University has developed this clinical study to evaluate the safety and effectiveness of Olanzapine in preventing migraine headaches.

Detailed description:

Arms:
arm 1: Olazepam arm 2: None

Interventions: intervention 1: Olanzapine during first intervention period and placebo during second intervention period intervention 2: Placebo during first intervention period, then olanzapine during second intervention period
Intervention descriptions: intervention 1: Olanzapine (5-10 mg) daily during first intervention period, then placebo(matching)druing second intervention period (after a washout period) intervention 2: Placebo (matching) during first intervention period, then olanzapine (5-10 mg. daily) during the second intervention period (after a washout phase).

Protocol document: